Wire · opportunities
'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The FDA has approved daraxonrasib (Rasonque), the first targeted RAS inhibitor drug for metastatic pancreatic ductal adenocarcinoma (PDAC), significantly improving survival outcomes for patients resistant to first-line treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.
◆ ◆ The Wire takeaway
You must update your pancreatic cancer treatment pipeline to integrate Rasonque now that it is FDA approved and showing doubled survival in second-line patients. This shifts market access and could make previous treatment options obsolete for your clinical offering.
◆ Coverage
20 sources · 26 Aug 2026
◆ Topics